SCHEMBL30749065

SCHEMBL30749065

COc1ccc(CNc2nc(C(=O)O)nc3c2C(C)(C)CN3c2ccc(OC3CCCCC3)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
MDM2 Q00987 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ASPH Q12797 1/20 0.35
KDM8 Q8N371 1/20 0.35
PDE9A O76083 1/20 0.34
MCHR1 Q99705 1/20 0.34
ALDH1A1 P00352 2/20 0.34
APP P05067 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748914 0.91 SLC26A6 (0.42) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL30748936 0.87 CCNE2 (0.41) PDE4APDE4BPDE4CPDE4DTDP1
SCHEMBL30749001 0.85 TDP1 (0.38) PDE4APDE4BPDE4CPDE4DNPC1
SCHEMBL30748757 0.73 ALDH1A1 (0.41) SMN1; SMN2KDM4EALDH1A1APPTSHR
SCHEMBL30748721 0.73 CCNE2 (0.43) SMN1; SMN2KDM4EALDH1A1APP
SCHEMBL31691289 0.72 KDM4E (0.41) SMN1; SMN2CDK5CDK5R1KDM4EALDH1A1
SCHEMBL31691227 0.71 APP (0.40) SMN1; SMN2KDM4EALDH1A1APP
SCHEMBL30748885 0.68 TNK2 (0.33) ALDH1A1APPTSHR
SCHEMBL3287494 0.64 TDP1 (0.51) PDE4APDE4BPDE4CPDE4DNPC1
SCHEMBL2144250 0.63 CLK4 (0.46) PDE4APDE4BPDE4CPDE4DNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT PDE4A 2322/4885PDE4B 2287/4885PDE4C 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.